0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Switching between anti-CGRP monoclonal antibodies and gepants

Session 4: Current strategies and the future ahead

Taoufik Alsaadi

MD, Chairman, Neurology Department, Chief Medical Officer, American Center for Psychiatry & Neurology (ACPN), Abu Dhabi

Download presentation

Previous

The nurse, the backbone of medical care

Next

Can we modify the course of migraine?

You Might Also Like

Related Embedded Video Item Thumbnail Pregnancy management and breastfeeding in migraine
Related Embedded Video Item Thumbnail Migraine preventative treatment recommendations/reimbursement conditions in the Nordics – What has changed in the last 5-6 years?
Related Embedded Video Item Thumbnail How to evaluate drug effectiveness in migraine?
Related Embedded Video Item Thumbnail Navigating recent studies: A Nordic perspective
Related Embedded Video Item Thumbnail Migraine management in elderly

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128